AI radiology company Aidoc revealed on Tuesday that the US Food and Drug Administration (FDA) has cleared the world's first AI solution for the treatment of cervical spine (C-spine) fractures.
This latest US FDA 510(k) clearance is reportedly the company's third in nine months and follows the recent US FDA clearance of the pulmonary embolism solution.
The company added that the AI-powered triage automatically prioritizes critical cases, ensuring that they are diagnosed by a radiologist in the most timely manner.
According to the company, the recent studies show that 54% of radiologists feel "burnt out" due to long work hours and on-the-job stress. AI-driven workflow triage is especially beneficial for empowering the radiologist by maintaining quality across the workflow, increasing confidence in treating critical patients on time, while making radiologists' work a lot more rewarding and less tedious.
In conjunction, the company's CEO Elad Walach will present its suite of AI-based workflow solutions at booth 513on an Ask Industry panel on the topic of 'AI in Practice – Where Are We Now?' at the SIIM 2019 annual meeting.
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency